Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type I Hypersensitivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Type I Hypersensitivity. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2022-003703-16 Sponsor Protocol Number: GR-2021-12375001 Start Date*: Information not available in EudraCT
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: The effect of phoSPHocreatine on mEdical emergency team (met) tREated patients: a randomized clinical trial protocol - SPHERE.
    Medical condition: Patients with worsening clinical condition requiring MET intervention and in general ward
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10045240 Type I hypersensitivity PT
    23.0 10047065 - Vascular disorders 10083659 Hypotensive crisis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019160-37 Sponsor Protocol Number: K-530 Start Date*: 2010-06-29
    Sponsor Name:Allergiklinikken
    Full Title: Intralymfatisk specifik immunterapi - som ny behandlingsmetode til græspollenallergikere
    Medical condition: Græspollen allergi
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001738 Allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003248-36 Sponsor Protocol Number: 61383082 Start Date*: 2011-09-30
    Sponsor Name:Central Military Hospital
    Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.
    Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016335 Feeling hot and cold LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037872 Rash NOS LLT
    14.0 10037175 - Psychiatric disorders 10032168 Other insomnia LLT
    14.0 10007541 - Cardiac disorders 10008481 Chest pain - cardiac LLT
    14.0 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    14.0 10029205 - Nervous system disorders 10048324 Dizziness aggravated LLT
    14.0 10029205 - Nervous system disorders 10033777 Paraesthesia distal LLT
    14.0 10022891 - Investigations 10050786 Fasting blood glucose increased LLT
    14.0 10018065 - General disorders and administration site conditions 10022096 Injection site reaction NOS LLT
    14.0 10021881 - Infections and infestations 10034838 Pharyngitis NOS LLT
    14.0 10018065 - General disorders and administration site conditions 10016259 Fatigueability LLT
    14.0 10021428 - Immune system disorders 10020762 Hypersensitivity type I LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048412 Back pain aggravated LLT
    14.0 10021428 - Immune system disorders 10020756 Hypersensitivity reaction LLT
    14.0 10017947 - Gastrointestinal disorders 10028822 Nauseated LLT
    14.0 10047065 - Vascular disorders 10048347 Flushing aggravated LLT
    14.0 10029205 - Nervous system disorders 10024857 Loss of consiousness LLT
    14.0 10029205 - Nervous system disorders 10019218 Headache NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037096 Pruritus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003019-39 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study
    Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001738 Allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004391-11 Sponsor Protocol Number: RCC-DC-2011 Start Date*: 2012-02-08
    Sponsor Name:Masaryk University
    Full Title: Treatment of metastatic renal cell carcinoma using interleukin-12 secreting dendritic cells. Phase I/II clinical trial.
    Medical condition: Metatastic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003934-28 Sponsor Protocol Number: SPON1455-15 Start Date*: 2016-03-04
    Sponsor Name:Cardiff University
    Full Title: Enhanced Epidermal Antigen Specific Immunotherapy trial -1 (EE-ASI-1): A Phase 1a study of gold nanoparticles administered intradermally by microneedles to deliver immunotherapy with a proinsulin d...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003699-60 Sponsor Protocol Number: KIBB01 Start Date*: 2018-09-28
    Sponsor Name:Karolinska Institutet
    Full Title: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal...
    Medical condition: Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV.
    Disease:
    Population Age: In utero, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2013-002775-17 Sponsor Protocol Number: 1010 Start Date*: 2013-10-29
    Sponsor Name:Andromeda Biotech Ltd
    Full Title: OPEN-LABEL STUDY TO EVALUATE LONG TERM SAFETY AND TREATMENT EFFECT OF DIAPEP277® IN SUBJECTS WHO HAVE COMPLETED STUDY 1001
    Medical condition: Type I diabetes
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004590-30 Sponsor Protocol Number: R10933-10987-COV-2121 Start Date*: 2022-09-23
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Phase 2a, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab and Imdevim...
    Medical condition: Coronavirus disease 2019
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-000994-39 Sponsor Protocol Number: BRD 06/2-D Start Date*: 2008-05-27
    Sponsor Name:Centre Hospitalier Universitaire de Nantes
    Full Title: Evaluation de l'intérêt d'un traitement par hydroquinidine pour la prise en charge des patients atteints d'un syndrome de Brugada à risque rythmique élevé et implantés d'un défibrillateur
    Medical condition: Patients with syndroma of Brugada who have an automatic implantable cardiac defibrillator
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059027 Brugada syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-001805-28 Sponsor Protocol Number: POM-002 Start Date*: 2012-07-03
    Sponsor Name:BioMarin Pharmaceutical Inc
    Full Title: A Long-Term Study for Extended BMN 701Treatment of Patients with Pompe Disease who have Participated in a BMN 701 Study
    Medical condition: Pompe disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10036143 Pompe's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005974-91 Sponsor Protocol Number: CT-P41_3.1 Start Date*: 2021-04-26
    Sponsor Name:Celltrion, Inc
    Full Title: A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteop...
    Medical condition: Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and micro architectural deterioration of bone tissue, with a low bone mineral density (BMD) and consequent increas...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000547-24 Sponsor Protocol Number: CCRG11-001 Start Date*: 2012-02-27
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study
    Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002286-32 Sponsor Protocol Number: 6125 Start Date*: 2009-08-10
    Sponsor Name:Queen Mary Medical University of London
    Full Title: Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukae...
    Medical condition: This is a phase I/ II trial to determine the efficacy of intravenous veltuzumab and epratuzmab either individually or together in combination with chemotherapy in patients with recurrent acute lymp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003890 B precursor type acute leukaemia LLT
    9.1 10003917 B-cell type acute leukaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006302-13 Sponsor Protocol Number: CT-BI Vacc-4x 2007/1 Start Date*: 2008-06-04
    Sponsor Name:Bionor Immuno AS
    Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART
    Medical condition: HIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 ...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022425-15 Sponsor Protocol Number: MK07 Start Date*: 2011-02-28
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study)
    Medical condition: Adenoid-cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001220 Adenoid cystic carcinoma of the oral cavity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004527-23 Sponsor Protocol Number: MM1636 Start Date*: 2017-03-14
    Sponsor Name:Center for Cancer Immune Therapy
    Full Title: Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine with Montanide to patients with metastatic malignant melanoma
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004959-35 Sponsor Protocol Number: GrassMATAMPL301 Start Date*: 2006-09-11
    Sponsor Name:Allergy Therapeutics (UK) Ltd
    Full Title: Efficacy and Safety/Tolerability of GrassMATAMPL, a Randomized, Placebo-Controlled, Double-Blind Study
    Medical condition: Type I respiratory hypersensitivity to cross-reacting grass pollens
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000712-42 Sponsor Protocol Number: IOM-115 Start Date*: 2004-12-22
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: Enhacement of the lower extremities computed tomography: IOMERON®-400 VS VISIPAQUE™-320 (ELECTIV).
    Medical condition: subjects with mild to moderate renal impairment (SCr =1.5-2.5 mg/dL and/or calculated CrCl = 10-60 mL/min) who undergo clinically-indicated IV contrast-enhanced MDCTA scanning of the lower extremit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000711-26 Sponsor Protocol Number: IOM-114 Start Date*: 2004-12-22
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: ABDOMINAL COMPUTED TOMOGRAPHY: IOMERON®400 VS VISIPAQUE™320 ENHANCEMENT (ACTIVE).
    Medical condition: subjects with mild to moderate renal impairment scheduled to undergo clinically-indicated IV contrast –enhanced MDCT scanning of the liver
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:19:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA